Related references
Note: Only part of the references are listed.Managing dyslipidemia in patients with Type 2 diabetes [Special Issue]
Brian Tomlinson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Evaluating Risk of Incident Diabetes Between Patients Who Used Lovastatin and Red Yeast Rice Prescriptions (LipoCol Forte): A Retrospective Cohort Study Based on a Real-World Database
Ta-Liang Chen et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Alan Chait et al.
DIABETES (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE ALGORITHM-2020 EXECUTIVE SUMMARY
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2020)
Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Genovefa D. Kolovou et al.
CURRENT VASCULAR PHARMACOLOGY (2019)
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
Hayato Tada et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2019)
Glucose and GLP-2 (Glucagon-Like Peptide-2) Mobilize Intestinal Triglyceride by Distinct Mechanisms
Priska Stahel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Francois Mach et al.
ATHEROSCLEROSIS (2019)
Statins and the potential for higher diabetes mellitus risk
Srikanth Yandrapalli et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
M. F. Wu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetes and lipid metabolism
Vasilios G. Athyros et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2018)
Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies
Prashanth Rawla et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2018)
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9
Rocco Romagnuolo et al.
PLOS ONE (2017)
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Marshall B. Elam et al.
JAMA CARDIOLOGY (2017)
Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Stephan Krahenbuhl et al.
DRUGS (2016)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2016)
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Peter P. Toth
VASCULAR HEALTH AND RISK MANAGEMENT (2016)
Non-high-density lipoprotein cholesterol: current status as cardiovascular marker
Rutger Verbeek et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails
Min Li et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2015)
Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
National Lipid Association Annual Summary of Clinical Lipidology 2015
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
Yan Zhang et al.
LIPIDS IN HEALTH AND DISEASE (2014)
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
Anders Berg Jorgensen et al.
EUROPEAN HEART JOURNAL (2013)
Hypertriglyceridemic Pancreatitis: Presentation and Management
Wayne Tsuang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients With Previous Myocardial Infarction From the China Coronary Secondary Prevention Study (CCSPS)
Jian-Jun Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effect of Xuezhikang, an extract from red yeast chinese rice, on coronary events in a Chinese population with previous myocardial infarction
Zongliang Lu et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Sandeep Bansal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: A subgroup analysis of elderly subjects from the china coronary secondary prevention study
Ping Ye et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2007)
Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: Subgroup analysis of patients with type 2 diabetes from China Coronary Secondary Prevention Study (CCSPS)
Shui-ping Zhao et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
DB Hunninghake et al.
CORONARY ARTERY DISEASE (2004)
Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease
SP Zhao et al.
CIRCULATION (2004)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease
SP Zhao et al.
ATHEROSCLEROSIS (2003)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
